Lorence Kim
Director/Board Member at CENCORA, INC.
Net worth: 2 M $ as of 2024-03-30
Profile
Lorence H.
Kim is the founder of Ascenta Capital, which was founded in 2023.
He is currently an Independent Director at Cencora, Inc., Cowen, Inc., Revolution Medicines, Inc., and ADARx Pharmaceuticals, Inc. He is also a Director at Flare Therapeutics, Inc. and Abata Therapeutics, Inc. Dr. Kim is a Trustee at Prep for Prep and a Member-Governors Board at American Red Cross, Inc. In the past, he held the position of Chief Financial Officer at ModernaTX, Inc. from 2014 to the present.
Prior to that, he worked as a Managing Director at Goldman Sachs & Co. LLC from 1999 to 2014.
He was also an Independent Director at Cowen, Inc. from 2022 to 2023, an Independent Director at Seres Therapeutics, Inc. from 2014 to 2020, and a Venture Partner at Third Rock Ventures LLC from 2020 to 2022.
Dr. Kim received his undergraduate degree from Harvard University in 1995.
He also holds an MBA from The Wharton School of the University of Pennsylvania, a doctorate from Perelman School of Medicine, and a doctorate from the University of Pennsylvania School of Veterinary Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-09-25 | 53,500 ( 0.03% ) | 2 M $ | 2024-03-30 | |
CENCORA, INC.
0.00% | 2024-03-11 | 2,735 ( 0.00% ) | 664 578 $ | 2024-03-30 |
Lorence Kim active positions
| Companies | Position | Start |
|---|---|---|
| REVOLUTION MEDICINES, INC. | Director/Board Member | 2022-07-11 |
| CENCORA, INC. | Director/Board Member | 2022-09-30 |
| COWEN INC. | Director/Board Member | 2022-02-14 |
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Director of Finance/CFO | - |
| Ascenta Capital | Founder | 2022-12-31 |
ADARx Pharmaceuticals, Inc.
 ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services ADARx Pharmaceuticals, Inc. operates as RNA base-editing company. The company is headquartered in San Diego, CA. | Director/Board Member | 2023-01-19 |
Prep for Prep
 Prep for Prep Miscellaneous Commercial ServicesCommercial Services Prep for Prep is an educational and leadership development program that was founded in 1978. The non-profit company is based in New York, NY. The program prepares and places promising students of color into independent schools and provides them with ongoing support and life-changing opportunities. The organization has more than 5,000 members, which proves that academic and professional success exists in all racial and ethnic groups and socioeconomic classes. | Director/Board Member | - |
American Red Cross, Inc.
 American Red Cross, Inc. Services to the Health IndustryHealth Services American Red Cross, Inc. provides individual and family social services. It is a humanitarian organization led by volunteers and guided by its Congressional Charter and the Fundamental Principles of the International Red Cross Movement, will provide relief to victims of disaster and help people prevent, prepare for, and respond to emergencies. The company was founded in 1881 and is headquartered in Kansas City, MO. | Director/Board Member | - |
Flare Therapeutics, Inc.
 Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Director/Board Member | - |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Former positions of Lorence Kim
| Companies | Position | End |
|---|---|---|
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░ ░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Lorence Kim
| Harvard University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Perelman School of Medicine | Doctorate Degree |
| University of Pennsylvania School of Veterinary Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| CENCORA, INC. | Distribution Services |
| SERES THERAPEUTICS, INC. | Health Technology |
| REVOLUTION MEDICINES, INC. | Health Technology |
| MODERNA, INC. | Health Technology |
| Private companies | 10 |
|---|---|
Goldman Sachs & Co. LLC
 Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |
Prep for Prep
Prep for Prep Miscellaneous Commercial ServicesCommercial Services Prep for Prep is an educational and leadership development program that was founded in 1978. The non-profit company is based in New York, NY. The program prepares and places promising students of color into independent schools and provides them with ongoing support and life-changing opportunities. The organization has more than 5,000 members, which proves that academic and professional success exists in all racial and ethnic groups and socioeconomic classes. | Commercial Services |
American Red Cross, Inc.
American Red Cross, Inc. Services to the Health IndustryHealth Services American Red Cross, Inc. provides individual and family social services. It is a humanitarian organization led by volunteers and guided by its Congressional Charter and the Fundamental Principles of the International Red Cross Movement, will provide relief to victims of disaster and help people prevent, prepare for, and respond to emergencies. The company was founded in 1881 and is headquartered in Kansas City, MO. | Health Services |
Cowen, Inc.
 Cowen, Inc. Investment Banks/BrokersFinance Cowen, Inc. engages in the provision of financial services. It operates through following the segments: Operating Company and Asset Company. The Operating Company segment consists of the Cowen Investment Management, Investment Banking, Markets, and Research divisions. The Asset Company segment consists of the firm’s private investments, private real estate investments, and other legacy investment strategies. The firm offers investment banking services, equity and credit research, sales and trading, prime brokerage, global clearing, commission management services, and actively managed alternative investment products. The company was founded in 1918 and is headquartered in New York, NY. | Finance |
ModernaTX, Inc.
ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. | Health Technology |
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services ADARx Pharmaceuticals, Inc. operates as RNA base-editing company. The company is headquartered in San Diego, CA. | Commercial Services |
Flare Therapeutics, Inc.
Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Health Technology |
Abata Therapeutics, Inc.
 Abata Therapeutics, Inc. BiotechnologyHealth Technology Abata Therapeutics, Inc. is a biotech company based in Watertown, MA. Abata Therapeutics is focused on developing engineered Treg cell therapies for severe autoimmune and inflammatory diseases. The American company's lead programs are in ind-enabling studies for progressive multiple sclerosis and type 1 diabetes, both of which are tissue-specific autoimmune diseases with significant unmet needs. The company has developed a differentiated product engine to create tissue-specific, robust, and durable therapies. Abata Therapeutics was launched by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara Biocapital, and the JDRF T1D Fund. The company was founded in 2021 by Richard Ransohoff and the CEO is Samantha Singer. | Health Technology |
| Ascenta Capital | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Lorence Kim
